Supercharging Immunotherapy

More about us

19 Oct 2020

Jean-Charles Soria, M.D., Ph.D., is Professor of Medicine and Medical Oncology…

16 Sep 2020

Article demonstrates promising preclinical results for the novel cancer…

16 Sep 2020

HOOKIPA Fireside Chat: Wednesday, September 23rd at 12:00 PM ET, with Joern…

13 Aug 2020

3 Aug 2020

The United States Patent and Trademark Office (USPTO) and the European Patent…

22 Jun 2020

Interim data demonstrate that HB 101 is well tolerated and HB-101 elicits T…

all news

fancy black and blue t-cell 3d scientific images immune system

We work to reprogram the immune system to more effectively combat cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring. We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.

Supercharging Immunotherapy

News

HOOKIPA Appoints Prof. Jean-Charles Soria to its Board of Directors

Publication on HB-201 in peer reviewed, open access journal OncoImmunology

HOOKIPA Pharma to Present at SVB Leerink’s CybeRx Series Vaccine Forum

HOOKIPA Pharma Reports Second Quarter 2020 Financial Results and Provides a…

HOOKIPA Announces Issuance of US and European Patents

HOOKIPA Announces Positive Phase 2 Interim Safety and Immunogenicity Results…

Our Mission

Our Pipeline

Careers